Surgery and radiotherapy are the most commonly used lines of treatment and currently the only approved molecular targeted therapy for head and neck cancer is cetuximab (Erbitux; ImClone Systems Inc., New York, NY), a monoclonal antibody inhibitor of epidermal growth factor receptor (EGFR). This evidence concerns the gene EGFR and head and neck cancer.